Drug Type Small molecule drug |
Synonyms Eucreas, Galvumet, Galvus Met + [21] |
Target |
Action inhibitors, activators |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors), PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (14 Nov 2007), |
Regulation- |
Molecular FormulaC21H37ClN8O2 |
InChIKeyPQETUJCOOSLMAX-OGDHSBAZSA-N |
CAS Registry2446159-61-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus | Australia | 13 Dec 2010 | |
Diabetes Mellitus, Type 2 | European Union | 14 Nov 2007 | |
Diabetes Mellitus, Type 2 | Iceland | 14 Nov 2007 | |
Diabetes Mellitus, Type 2 | Liechtenstein | 14 Nov 2007 | |
Diabetes Mellitus, Type 2 | Norway | 14 Nov 2007 |
Phase 4 | 40 | (Vildagliptin and Metformin) | ehwkvbpczq(ulwntvuejz) = apxrnkpguf dxjfnwrmlw (lsnqskeqam, 1.48) View more | - | 11 Jul 2017 | ||
(Glimepiride and Metformin) | ehwkvbpczq(ulwntvuejz) = cyxwnkoyer dxjfnwrmlw (lsnqskeqam, 1.08) View more | ||||||
Phase 4 | 156 | (Vildagliptin (LAF237)) | xyamtngsrg(sdfxdbbdhk) = ymybpfodzw xsmcovzpad (lcbgfqoqry, 0.06) View more | - | 01 Mar 2016 | ||
Insulin+Metformin (Placebo) | xyamtngsrg(sdfxdbbdhk) = nlktrervwm xsmcovzpad (lcbgfqoqry, 0.06) View more | ||||||
Phase 3 | 171 | Placebo (Placebo) | nhteobgbnu(uqyzhgmeuw) = gallanpmmt plidduitgs (fwrballawx, 0.08) View more | - | 23 Feb 2015 | ||
(LMF237 50/250 mg) | fvulrnvdlf(quauijlwtw) = yzjftlleng kiyykvnhsw (icfzjinopn, 0.06) View more |